| Date |
Report No. |
Title |
| Date Sept. 7, 2011 |
Report No. GAO-11-801 |
Title
United States Government Accountability Office GAO
September 2011 Report to the Ranking Member, Committee on Rules, House of Representatives ANTIBIOTIC RESISTANCE Agencies Have Made Limited Progress Addressing Antibiotic Use in Animals GAO-11-801 September 2011 ANTIBIOTIC RESISTANCE
Agencies Have Made Limited Progress Addressing Antibiotic Use in Animals
Highlights of GAO-11-801, a report to the R... |
| Date June 1, 2011 |
Report No. GAO-11-406 |
Title
United States Government Accountability Office GAO
June 2011 Report to the Committee on Agriculture, House of Representatives ANTIBIOTIC RESISTANCE Data Gaps Will Remain Despite HHS Taking Steps to Improve Monitoring GAO-11-406 June 2011 ANTIBIOTIC RESISTANCE
Accountability • Integrity • Reliability Data Gaps Will Remain Despite HHS Taking Steps to Improve Monitoring
Highlights of GAO-11-406, ... |
| Date May 31, 2011 |
Report No. GAO-11-457 |
Title
United States Government Accountability Office GAO
May 2011 Report to Congressional Committees PEDIATRIC RESEARCH Products Studied under Two Related Laws, but Improved Tracking Needed by FDA GAO-11-457 May 2011 PEDIATRIC RESEARCH
Accountability • Integrity • Reliability Products Studied under Two Related Laws, but Improved Tracking Needed by FDA
Highlights of GAO-11-457, a report to congressio... |
| Date July 30, 2010 |
Report No. GAO-10-798 |
Title
United States Government Accountability Office GAO
July 2010 Report to Congressional Requesters NEW DRUG APPROVAL FDA’s Consideration of Evidence from Certain Clinical Trials GAO-10-798 July 2010 NEW DRUG APPROVAL Highlights
Highlights of GAO-10-798, a report to congressional requesters Accountability Integrity Reliability FDA’s Consideration of Evidence from Certain Clinical Trials Why GAO Di... |
| Date Dec. 22, 2009 |
Report No. GAO-10-201 |
Title
United States Government Accountability Office GAO
December 2009 Report to Congressional Requesters BRAND-NAME PRESCRIPTION DRUG PRICING Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases GAO-10-201 December 2009 BRAND-NAME PRESCRIPTION DRUG PRICING Highlights
Highlights of GAO-10-201, a report to congressional requesters Accountability... |
| Date March 26, 2009 |
Report No. GAO-09-448T |
Title
United States Government Accountability Office GAO
For Release on Delivery Expected at 10:00 a.m. EDT Thursday, March 26, 2009 Testimony Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives HUMAN SUBJECTS RESEARCH Undercover Tests Show the Institutional Review Board System Is Vulnerable to Unethical Manipulation
Statement of Gregory D.... |
| Date Feb. 20, 2009 |
Report No. GAO-09-245 |
Title
United States Government Accountability Office GAO
February 2009 Report to Congressional Requesters NONPRESCRIPTION DRUGS Considerations Regarding a Behind-the-Counter Drug Class GAO-09-245 February 2009 NONPRESCRIPTION DRUGS Highlights
Highlights of GAO-09-245, a report to congressional requesters Accountability Integrity Reliability Considerations Regarding a Behind-the-Counter Drug Class Why GA... |
| Date Aug. 7, 2008 |
Report No. GAO-08-751 |
Title
United States Government Accountability Office GAO
August 2008 Report to Congressional Requesters FOOD AND DRUG ADMINISTRATION Approval and Oversight of the Drug Mifeprex GAO-08-751 August 2008 FOOD AND DRUG ADMINISTRATION Highlights
Highlights of GAO-08-751, a report to congressional requesters Accountability Integrity Reliability Approval and Oversight of the Drug Mifeprex Why GAO Did This Study... |
| Date May 22, 2007 |
Report No. GAO-07-898T |
Title
United States Government Accountability Office GAO
For Release on Delivery Expected at 10:00 a.m. EDT Tuesday, May 22, 2007 Testimony Before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives PEDIATRIC DRUG RESEARCH The Study and Labeling of Drugs for Pediatric Use under the Best Pharmaceuticals for Children Act
Statement of Marcia Crosse Director, Health Care G... |
| Date May 9, 2007 |
Report No. GAO-07-856T |
Title
United States Government Accountability Office GAO
For Release on Delivery Expected at 10:00 a.m. EDT May 9, 2007 Testimony Before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives DRUG SAFETY Further Actions Needed to Improve FDA’s Postmarket Decision-making Process
Statement of Marcia Crosse Director, Health Care GAO-07-856T May 9, 2007 DRUG SAFETY Highligh... |
| Date March 22, 2007 |
Report No. GAO-07-599T |
Title
United States Government Accountability Office GAO
For Release on Delivery Expected at 9:30 a.m. EDT March 22, 2007 Testimony Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives DRUG SAFETY FDA Needs to Further Address Shortcomings in Its Postmarket Decisionmaking Process
Statement of Marcia Crosse Director, Health Care GAO-07-599T Ma... |
| Date March 22, 2007 |
Report No. GAO-07-557 |
Title
United States Government Accountability Office GAO
March 2007 Report to Congressional Committees PEDIATRIC DRUG RESEARCH Studies Conducted under Best Pharmaceuticals for Children Act GAO-07-557 March 2007 PEDIATRIC DRUG RESEARCH Highlights
Highlights of GAO-07-557, a report to congressional committees Accountability Integrity Reliability Studies Conducted under Best Pharmaceuticals for Children Ac... |
| Date Nov. 17, 2006 |
Report No. GAO-07-49 |
Title
United States Government Accountability Office GAO
November 2006 Report to Congressional Requesters NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts GAO-07-49 November 2006 NEW DRUG DEVELOPMENT Highlights
Highlights of GAO-07-49, a report to congressional requesters Accountability Integrity Reliability Science, Busines... |
| Date March 31, 2006 |
Report No. GAO-06-402 |
Title
United States Government Accountability Office GAO
March 2006 Report to Congressional Requesters DRUG SAFETY Improvement Needed in FDA’s Postmarket Decision-making and Oversight Process GAO-06-402 March 2006 DRUG SAFETY Highlights
Highlights of GAO-06-402, a report to the Chairman, Committee on Finance, United States Senate and the Chairman, Committee on Energy and Commerce, House of Representat... |
| Date March 31, 2005 |
Report No. GAO-05-399 |
Title
United States Government Accountability Office GAO
March 2005 Report to Congressional Requesters HHS Efforts to Research and Inform the Public about Nonoxynol-9 and HIV GAO-05-399 a March 2005 HHS Highlights
Highlights of GAO-05-399, a report to congressional requesters Accountability Integrity Reliability Efforts to Research and Inform the Public about Nonoxynol-9 and HIV Why GAO Did This Study
P... |
| Date June 4, 2003 |
Report No. GAO-03-829 |
Title
United States General Accounting Office GAO
June 2003 Report to the Honorable Ron Wyden, U.S. Senate TECHNOLOGY TRANSFER NIH-Private Sector Partnership in the Development of Taxol GAO-03-829 Contents Letter
Results in Brief Background NIH-BMS Partnership Provided Research Results Critical to Developing Taxol’s Commercial Uses NIH Invested Heavily in Taxol-Related Research, but Federal Financial ... |
| Date July 6, 2001 |
Report No. GAO-01-754 |
Title
United States General Accounting Office GAO
July 2001 Report to Congressional Requesters WOMEN’S HEALTH Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement GAO-01-754 Contents Letter
Results in Brief Background FDA’s Regulation Not As Specific As Earlier Guidance NDA and IND Submissions Often Fail to Present Required Information NDAs Include Appropriate Numb... |
| Date May 8, 2001 |
Report No. GAO-01-705T |
Title
United States General Accounting Office GAO Testimony
Before the Committee on Health, Education, Labor and Pensions, U.S. Senate For Release on Delivery Expected at 9:30 a.m. Tuesday, May 8, 2001 PEDIATRIC DRUG RESEARCH Substantial Increase in Studies of Drugs for Children, But Some Challenges Remain
Statement of Janet Heinrich Director, Health Care—Public Health Issues GAO-01-705T Chairman Jeff... |
| Date Jan. 19, 2001 |
Report No. GAO-01-286R |
Title
United States General Accounting Office Washington, DC 20548 January 19, 2001 The Honorable Tom Harkin The Honorable Olympia J. Snowe The Honorable Barbara A. Mikulski United States Senate The Honorable Henry A. Waxman House of Representatives Subject: Drug Safety: Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women The Food and Drug Administration (FDA) approves drugs for sale... |
| Date Aug. 10, 2000 |
Report No. HEHS-00-140 |
Title
United States General Accounting Office GAO
August 2000 Report to Congressional Requesters PRESCRIPTION DRUGS Many Factors Affected FDA’s Approval of Selected “Pipeline” Drugs GAO/HEHS-00-140 Contents Letter Appendixes
Appendix I: Scope and Methodology 3 26 29 32 45 49 Appendix II: Approval Time Comparisons Appendix III: Approval Process for Claritin Appendix IV: Approval Process for Relafen... |
| Date Feb. 9, 2000 |
Report No. T-HEHS-00-61 |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 10:30 a.m. Wednesday, February 9, 2000 Testimony
Before the Subcommittees on Health and Environment, and Oversight and Investigations, Committee on Commerce, and Subcommittee on Health, Committee on Veterans’ Affairs, House of Representatives ADVERSE EVENTS Surveillance Systems for Adverse Events and Medical Errors
S... |
| Date Feb. 1, 2000 |
Report No. T-HEHS-00-53 |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 10:00 a.m. Tuesday, Feb. 1, 2000 Testimony
Before the Committee on Health, Education, Labor, and Pensions, U.S. Senate ADVERSE DRUG EVENTS Substantial Problem but Magnitude Uncertain
Statement of Janet Heinrich, Associate Director Health Financing and Public Health Issues Health and Human Services Division GAO/T-HEHS-0... |
| Date Dec. 14, 1999 |
Report No. HEHS-00-34 |
Title
United States General Accounting Office GAO
December 1999 Report to the Ranking Minority Member, Committee on Veterans’ Affairs, U.S. Senate VA HEALTH CARE VA’s Management of Drugs on Its National Formulary GAO/HEHS-00-34 GAO United States General Accounting Office Washington, D.C. 20548 Health, Education, and Human Services Division B-283993 December 14, 1999 The Honorable John D. Rockefeller... |
| Date Nov. 4, 1999 |
Report No. NSIAD-00-54R |
Title
United States General Accounting Washington, DC 20548 Office National Security and International Affairs Division B-284044 November 4, 1999 The Honorable Steve Buyer Chairman, Subcommittee on Military Personnel Committee on Armed Services House of Representatives Subject: Summary Vaccine of GAO’s Findinas on the Safetv and Efficacv of the Anthrax Dear Mr. Chairman: Concerns have been raised abou... |
| Date March 27, 1998 |
Report No. HEHS-98-72 |
Title
United States General Accounting Office GAO
March 1998 Report to Congressional Requesters DRUG ABUSE Research Shows Treatment Is Effective, but Benefits May Be Overstated GAO/HEHS-98-72 GAO United States General Accounting Office Washington, D.C. 20548 Health, Education, and Human Services Division B-279062 March 27, 1998 The Honorable Newt Gingrich House of Representatives The Honorable J. Dennis... |
| Date Oct. 14, 1997 |
Report No. HEHS-98-15R |
Title
t GAO United States General Accounting Offhe Washington, D.C. 20648 L~9GZ Health, Educathn and Human Services Division B-278145 October 14, 1997 The Honorable Connie Mack The Honorable John Rockefeller United States Senate Subject: Cancer Clinical Trials: Medicare Reimbursement Denials In order to determine whether new drugs are safe and effective, it is essential to conduct studies in which the d... |
| Date Sept. 12, 1996 |
Report No. T-HEHS-96-212 |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 10:00 a.m. September 12, 1996 Testimony
Before the Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Reform and Oversight, U. S. House of Representatives PRESCRIPTION DRUGS Implications of Drug Labeling and Off-Label Use
Statement of Sarah F. Jagger Director of Health Services Qua... |
| Date June 7, 1996 |
Report No. HEHS-96-80 |
Title
United States General Accounting Office GAO
June 1996 Report to Congressional Requesters COCAINE TREATMENT Early Results From Various Approaches G A O years
1921 - 1996 GAO/HEHS-96-80 GAO United States General Accounting Office Washington, D.C. 20548 Health, Education, and Human Services Division B-265688 June 7, 1996 The Honorable William F. Clinger, Jr. Chairman The Honorable Cardiss Collins Ran... |
| Date May 14, 1996 |
Report No. PEMD-96-7 |
Title
United States General Accounting Office GAO
May 1996 Report to the Ranking Minority Member, Committee on Science, House of Representatives CHOLESTEROL TREATMENT A Review of the Clinical Trials Evidence G A O years
1921 - 1996 GAO/PEMD-96-7 GAO United States General Accounting Office Washington, D.C. 20548 Program Evaluation and Methodology Division B-266080 May 14, 1996 The Honorable George E. Bro... |
| Date May 2, 1996 |
Report No. T-PEMD-96-9 |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 10:00 a.m. EST Thursday May 2, 1996 Testimony
Before the Subcommittee on Health and Environment, Committee on Commerce, House of Representatives FDA REVIEW TIMES Statement of Mary R. Hamilton, Ph.D. Director of Program Evaluation in Human Services Areas Program Evaluation and Methodology Division G A O years
1921 - 199... |
| Date March 28, 1996 |
Report No. T-HEHS-96-114 |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 9:30 a.m. Thursday, March 28, 1996 Testimony
Before the Special Committee on Aging, U.S. Senate PRESCRIPTION DRUGS AND THE ELDERLY Many Still Receive Potentially Harmful Drugs Despite Recent Improvements
Statement of Sarah F. Jaggar, Director Health Financing and Public Health Issues Health, Education, and Human Servic... |
| Date March 12, 1996 |
Report No. T-HEHS-96-102 |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 9:00 a.m. Tuesday, March 12, 1996 Testimony
Before the Committee on Governmental Affairs U.S. Senate SCIENTIFIC RESEARCH Continued Vigilance Critical to Protecting Human Subjects
Statement of Sarah F. Jaggar, Director Health Financing and Public Health Issues Health, Education, and Human Services Division G A O years
1... |
| Date March 8, 1996 |
Report No. HEHS-96-72 |
Title
United States General Accounting Office GAO
March 1996 Report to the Ranking Minority Member, Committee on Governmental Affairs, U.S. Senate SCIENTIFIC RESEARCH Continued Vigilance Critical to Protecting Human Subjects G A O years
1921 - 1996 GAO/HEHS-96-72 GAO United States General Accounting Office Washington, D.C. 20548 Health, Education, and Human Services Division B-259279 March 8, 1996 The H... |
| Date Feb. 21, 1996 |
Report No. T-PEMD-96-6 |
Title
United States General Accounting Office Testimony
Before the Committee on Labor and Human Resources U.S. Senate For Release on Delivery Expected at 9~30a.m. EST Wednesday February 2 1,1996 Statement of Mary R. Hamilton, Ph.D. Director of Program Evaluation in the Human Services Area Program Evaluation and Methodology Division GAOfI’ -PEMD-96-6 Dear Madam Chairman: In October 1995, GAO issued a r... |
| Date Oct. 20, 1995 |
Report No. PEMD-96-1 |
Title
United States General Accounting Office GAO
October 1995 Report to Congressional Requesters FDA DRUG APPROVAL Review Time Has Decreased in Recent Years GAO/PEMD-96-1 GAO United States General Accounting Office Washington, D.C. 20548 Program Evaluation and Methodology Division B-266023 October 20, 1995 The Honorable Nancy Landon Kassebaum Chairman The Honorable Edward M. Kennedy Ranking Minority Me... |
| Date Oct. 1, 1995 |
Report No. AA-95-18(4) |
Title
United States General Accounting Office GAO GAO
October 1995 Health, Education and Human Services
~~~Division ET **E- rNational and Public Health Issues Issue Area Active Assignments 0 6c 5/
GAO/AA-95-18(4) 55o I Foreword This report was prepared primarily to inform Congressional members and key staff of ongoing assignments in the General Accounting Office's National and Public Health Issues issue... |
| Date Sept. 13, 1995 |
Report No. HEHS-95-141 |
Title
United States General Accounting Office GAO
September 1995 Report to the Chairman and Ranking Minority Member, Human Resources and Intergovernmental Relations Subcommittee, House Committee on Government Reform and Oversight CANCER DRUG RESEARCH Contrary to Allegation, NIH Hydrazine Sulfate Studies Were Not Flawed GAO/HEHS-95-141 GAO United States General Accounting Office Washington, D.C. 20548 He... |
| Date July 24, 1995 |
Report No. HEHS-95-152 |
Title
United States General Accounting Office GAO
July 1995 Report to the Honorable Ron Wyden, House of Representatives PRESCRIPTION DRUGS AND THE ELDERLY Many Still Receive Potentially Harmful Drugs Despite Recent Improvements GAO/HEHS-95-152 GAO United States General Accounting Office Washington, D.C. 20548 Health, Education, and Human Services Division B-259603 July 24, 1995 The Honorable Ron Wyden H... |
| Date April 28, 1995 |
Report No. HEHS-95-90 |
Title
United States General Accounting Office 3AO Report to the Chairman, Special Committee on Aging, U.S. Senate Apil 1995 PRESCRIPTION DRUG
PRICES Official Index Overstates Producer Price Inflation GAO/IEHS-95-90 GAO ~~~~~~Washington,D.C. 20548 United States General Accounting Office Health, Education, and Human Services Division B-260293 April 28, 1995 The Honorable William S. Cohen Chairman, Special... |
| Date Dec. 15, 1994 |
Report No. HEHS-95-34R |
Title
GAO United States General Accounting Office Washington, D.C. 20648 Health, Education and Human Services Division B-232863 December 15, 1994 The Honorable Tim Valentine, Chairman The Honorable Tom Lewis, Ranking Minority Member The Honorable Peter I. Blute Subcommittee on Technology, Environment and Aviation Committee on Science, Space, and Technology House of Representatives Members of Congress ha... |
| Date Aug. 12, 1994 |
Report No. HEHS-94-200R |
Title
United States General Accounting Offlce WashIngton, D.C. 20548 Health, Education and Human Services Divlslon rn3y/- B-226377 August 12, 1994 The Honorable Henry A. Waxman Chairman, Subcommittee on Health and the Environment Committee on Energy and Commerce House of Representatives Dear Mr. Chairman: As the debate over U.S. health care reform continues, prescription drug prices remain the subject o... |
| Date July 27, 1994 |
Report No. T-HEHS-94-213 |
Title
United States General Accounting Office GAO
For Release on Delivery Expected at 930 a.m., EST Wednesday July 27, 1994 Testimony
Before the Committee on Governmental Affairs United States Senate PRESCRIPTION DRUGS Prices and Regulation in Canada and Europe
Statement of Sarah F. Jaggar Director, Health Financing and Policy Issues Health, Education, and Human Services Division Messrs. Chairmen and Me... |
| Date May 17, 1994 |
Report No. HEHS-94-30 |
Title
Health, Education, and Human Services Division B-251111 May 17,1994 The Honorable David H. Pryor Chairman, Special Committee on Aging United States Senate Dear Mr. Chairman: This report, prepared at your request, examines how other countries regulate prescription drug prices, how those policies affect drug prices, and how they affect pharmaceutical research and development. As arranged with your ... |
| Date May 13, 1994 |
Report No. GGD-94-139 |
Title
United States General Accounting Office “GAO ’
May 1994 Report to the Chairman, Special Committee on-Aging, U.S. Senate TAX POLICY Pharmaceutical Industry’ Use of the s Reseafch Tax Credit GAOIGGD-94-139 B-256950 May 13, 1994 The Honorable David Pryor Chairman, Special Committee on Aging United States Senate Dear Mr. Chairman: This report is the second part of a response to your request to r... |
| Date Jan. 12, 1994 |
Report No. HEHS-94-29 |
Title
United States General Accounting Office GAO
January 1994 Report to the Chairman, Subcommittee on Health and the Environment, Committee on Energy and Commerce, House of Representatives ’ PRESCRIPTION DRUGS Companies Qpically Charge More in the United States Than in the United Kingdom GAO United States General Accounting Office Washington, D.C. 20648 Human Health, Education, and Services Division ... |
| Date Oct. 13, 1993 |
Report No. HRD-94-1R |
Title
.GAO United states General Acconnting OfIke Wwhtngton, D.C. 20648 Human Resources Division B-250909 October 13, 1993 The Honorable Fortney H, (Pete) Stark Chairman, Subcommittee on Health Committee on Ways and Means House of Representatives Dear Mr. Chairman:
This letter responds to your request that.we evaluate the methodology and data used by the Health Care Financfng Administration (HCFA) to es... |
| Date April 12, 1993 |
Report No. HRD-93-81 |
Title
IJnited States General Accounting Office Report to Congressional Requesters FDA PREMARKET APPROVAL Process of Approving Lodine as a Drug GAO United States General Accounting Of’ flce Washington, D.C. 20548 Human Resource6 Division B-262669 April 12,1903 The Honorable William J. Hughes Chairman, Subcommittee on Intellectual Property and Judicial Administration Committee on the Judiciary House of ... |
| Date Feb. 22, 1993 |
Report No. T-HRD-93-5 |
Title
United StatesGenerd kmmtinp Office GAO
For Release D&very on Eqwedat 1050 am., EST
Mai&ly Testimony
Before the Subcommitteeon Health and the Environment; Committee on Energy and Commerce, _ House of Representatives PRESCRIPTIONDRUGS CompaniesTypically Charge More in the United States Than in Canada
Statementof Janet L. SWes, Director, Health Financing and Policy Issues, Human ResourcesDivision Fcb... |
| Date Feb. 17, 1993 |
Report No. HRD-93-51 |
Title
PRESCRIPTION DRUG PRICES i 48527 Ill RESTRICTED-Not to be released outside the General Accounting Office unless specifically approved by the Office of Congressional Relations. I 5Sb’ f58 RELEASED GAO United States General Accounting Office Washington, D.C. 20548 Human Resources Division B-247942 February 17, 1993 The Honorable David Pryor Chairman, Special Committee on Aging United States Senate... |
| Date Oct. 29, 1992 |
Report No. HRD-93-17 |
Title
IJnited States General Accounting Office Report to Congressional Requesters Octobt?r 1992 WOMEN’ HEALTH S FDA Needs to Ensure More Study of Gender Differences~ in Prescription Drug Testing, II II
147861 GAO/HRD-93-1’ 7 . United States General Accounting Office Washington, D.C. 20548 Human Resources Division B-243898 October 29,1992 The Honorable Henry A. Waxman Chairman, Subcommittee on Health... |
